Skip to main content
eSRS symposium

Register for the eSRS Satellite Symposium : From new tracers developments to routine clinical applications on Synthera® + platform

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.  In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.  When?  May 20th 4-5pm CET (Central European Time)   REGISTER What will you learn ?   Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark.   In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.    Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research & Development at Positron Pharma in Santiago, Chile.  He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform.     You can join this symposium even if you don’t attend eSRS meeting.
See more

Watch the webinar: The Role of Specific PET PSMA imaging and SBRT in the Management of Prostate Cancer

Thank you  Dr. Jeremie Calais, Dr. Stefan Korber and Dr. Kai Schubert for your instructive presentations!  Did you miss the webinar? Watch the recording In addition to all questions answered at the end of this webinar, here are a few remaining ones, which the speakers kindly answered: Do you think that PET imaging in treatment position needs to be done systematically (in order to decrease irradiation dose exposure) ? Dr Calais: No. This is not like head and Neck or lung. Rectal and bladder filling are too complex to really have exact repositioning from PSMA PET to treatment table. Dr Schubert: Treatment position is not absolutely necessary, of course favorable. Different positions between treatment planning CT and ‘diagnostic’ imaging can be taken care of by deformable image registration, but there are limitations and additional QA would be necessary.   Is there any comparison between PSMA-Targeted therapy and SBRT?  Dr Calais :  No (not yet). Trials of PSMA MRT for oligometastatic disease are underway. My personal opinion is that it may not be the best application as a single agent therapy because the local control is inferior than with SBRT. However it can treat the microscopic and small lesions, so maybe the combination of both is probably a good approach.   When should we re-image after PSMA guided MDT? after changes in PSA? Dr Calais : At least 4 months after the end of SBRT ( for the local control).Otherwise if suspicion of new lesions based on PSA rise after NADIR or other imaging suspicion or clinical symptom. Dr Korber: I think, checking the PSA is adequate. Sure, if the PSA is rising again, new imaging (e.g. another PSMA-PET/CT) should be evaluated.
See more

WEBINAR: the Role of Tumor-Specific PET imaging and SBRT in the Management of Prostate Cancer!

IBA invites you to attend a free webinar presented by 3 leading personalities in Nuclear Medicine, Radiation Oncology and Medical Physics: Dr Jeremie Calais, PD Dr. med. Stefan Körber and Dr. Kai Schubert.  In this webinar, the speakers will highlight the synergy between highly sensitive imaging, the definition of an intermediate stage between non-disseminated tumor and widespread metastatic disease (oligometastatic state) and high-precision radiation therapy (Stereotactic Body Radiation Therapy - SBRT) focused to treat the oligometastatic lesions. When? April 26th, 5-6 pm CET  REGISTER What will you learn from the webinar ?  •      Impact of PSMA PET on management of patients with oligo metastatic prostate cancer By Dr. Jeremie Calais, Director of the Clinical Research Program of the Nuclear Medicine and Theranostics Division at UCLA.  Dr Calais will cover the concept of oligometastatic disease in prostate cancer patients and the impact of PSMA PET imaging on the therapy management of those patients.   •    The Role of SBRT in the treatment of oligometastatic prostate cancer: Why & how SBRT for these patients By PD Dr. med. Stefan Körber,  First Senior Medical Doctor at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany Dr. Körber will describe how the oligometastatic status of prostate cancer patients is defined on the basis of PSMA PET/CT and which strategies and modalities are applied for SBRT treatment of these patients    •    Quality assurance for SBRT treatments By Dr. Kai Schubert, Medical Physicist at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany. The extremely high precision of SBRT requires an extensive program of Quality Assurance, both for the treatment machines as for the patient-specific treatment plans. Dr. Schubert will explain current strategies and future developments in this field.  REGISTER  
See more


Synthera® +


Cyclone® KIUBE


IntegraLab ONE


IntegraLab PLUS



IBA Synthera +

IBA Synthera +

Synthera®+ remains the most compact module on the market: up to 3 synthesizers can fit into a standard hot cell. Synthera®+ and Synthera®+ HPLC have both been fully redesigned to meet the most demanding production schedule of different radiotracers without opening the hot cell (less intervention, more safety). Synthera®+ can be equipped with the automatic IFP Loader (disposable production cassette dispenser) which can stack up to 4 cassettes. This allows it to perform consecutive runs of different compounds without opening the hot cell, resulting in nearly zero radiation exposure to the operator. This unique feature multiplies the capability of each module by a factor of four.


IBA is launching a new cyclotron for its 35th anniversary.

Users Meeting 2019 - Krasnoyarsk

Users Meeting 2019 - Krasnoyarsk

IBA organizes biennial users meetings involving all PET customers all around the world. Our experience shows that gathering people together encourages creativity and helps IBA to develop priorities jointly with customers.


IBA integralab presentation - short version

INTEGRALAB®PLUS is a fully integrated solution, combining equipment and services for establishing a radiopharmaceutical GMP production centre tailored to your precise needs. Our approach is truly comprehensive, taking your project from building design through to ongoing production with full regulatory compliance and the selection, integration, installation and qualification of equipment that meets your radioisotope production goals